Skip to Content
Merck
  • Excessive E2F Transcription in Single Cancer Cells Precludes Transient Cell-Cycle Exit after DNA Damage.

Excessive E2F Transcription in Single Cancer Cells Precludes Transient Cell-Cycle Exit after DNA Damage.

Cell reports (2020-12-03)
Hendrika A Segeren, Lotte M van Rijnberk, Eva Moreno, Frank M Riemers, Elsbeth A van Liere, Ruixue Yuan, Richard Wubbolts, Alain de Bruin, Bart Westendorp
ABSTRACT

E2F transcription factors control the expression of cell-cycle genes. Cancers often demonstrate enhanced E2F target gene expression, which can be explained by increased percentages of replicating cells. However, we demonstrate in human cancer biopsy specimens that individual neoplastic cells display abnormally high levels of E2F-dependent transcription. To mimic this situation, we delete the atypical E2F repressors (E2F7/8) or overexpress the E2F3 activator in untransformed cells. Cells with elevated E2F activity during S/G2 phase fail to exit the cell cycle after DNA damage and undergo mitosis. In contrast, wild-type cells complete S phase and then exit the cell cycle by activating the APC/CCdh1 via repression of the E2F target Emi1. Many arrested wild-type cells eventually inactivate APC/CCdh1 to execute a second round of DNA replication and mitosis, thereby becoming tetraploid. Cells with elevated E2F transcription fail to exit the cell cycle after DNA damage, which potentially causes genomic instability, promotes malignant progression, and reduces drug sensitivity.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Bovine Serum Albumin, pH <5.0, powder
Sigma-Aldrich
MISSION® esiRNA, targeting human CDK1
Sigma-Aldrich
Fluoroshield with DAPI, histology mounting medium
Sigma-Aldrich
MISSION® esiRNA, targeting human TP53
Sigma-Aldrich
MISSION® esiRNA, targeting human RB1
Sigma-Aldrich
MISSION® esiRNA, targeting human E2F8
Sigma-Aldrich
MISSION® esiRNA, targeting human CDK2
Sigma-Aldrich
MISSION® esiRNA, targeting human E2F7